The Quinism Foundation Calls on GSK to Take Action to Better Emphasize Limitations of Use for Krintafel® (Tafenoquine)
Retrieved on:
Friday, February 28, 2020
Consequently, GSK must take appropriate action to better emphasize that approved use of Krintafel is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy."
Key Points:
- Consequently, GSK must take appropriate action to better emphasize that approved use of Krintafel is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy."
- [4] "Publicly-available data support a conclusion that tafenoquine shares the liability to CNS neurotoxicity of related 8-aminoquinolines," said Dr. Nevin.
- Dr. Nevin is a board-certified occupational medicine and preventive medicine physician and former U.S. Army medical officer and epidemiologist.
- The effects of pentaquine,isopentaquine, primaquine, and pamaquine on the central nervous system of the rhesus monkey.